Hormonal
Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) and triple agonists (e.g., retatrutide) produce significantly greater reductions in body weight and HbA1c compared to selective GLP-1 receptor agonists or placebo in individuals with type 2 diabetes and obesity.
For individuals with obesity or type 2 diabetes, dual GIP/GLP-1 agonists like tirzepatide offer superior weight loss and blood sugar control compared to older GLP-1-only drugs. Treatment typically starts at a low dose (2.5 mg weekly) and increases gradually to 5, 10, or 15 mg to manage side effects. Clinical trials show up to 20% body weight reduction in non-diabetic obese adults over two years.
Emerging evidence suggests that dual GIP/GLP-1 receptor agonists and triple GIP/GLP-1/glucagon receptor agonists provide beneficial metabolic effects in individuals with type 2 diabetes and obesity.
Why this rating
Supported by multiple Phase III clinical trials (SURPASS, SURMOUNT) with large sample sizes.
Source
Physiology and clinical applications of GIP
Shunsuke Yamane et al. · Endocrine Journal · 2025
DOI 10.1507/endocrj.ej25-0087
More from this paper
- Physiological levels of GIP promote fat accumulation and insulin resistance in the context of high-fat diets and aging, acting as a 'thrifty hormone' that stores nutrients.Good
- GIP secretion is robustly stimulated by dietary lipids (fats) via GPR40, GPR120, and GPR119 receptors, with fat inducing a threefold higher GIP response compared to an oral glucose tolerance test.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →